Sprint Bioscience on preclinical focus and plans for long-term independence

Anne-Marie Wenthzel, VP of business development at Sprint Bioscience, chats with Sten Stovall during the BIO-Europe Spring partnering conference in Stockholm, Sweden, about the company's business model and preclinical checklist for success. She explains Sprint's long-term business plan to be a sustainable independent drug developer, why the company chose to go public in 2014 and what we should expect to see from Sprint in the future.

Interviewer: Sten Stovall – Senior Editor, Pharma Intelligence, In Vivo/Pink Sheet/Scrip
Interviewee: Anne-Marie Wenthzel – VP, Business Development, Sprint Bioscience